7-[(E)-3-oxo-3-[4-(1,3-thiazol-2-ylmethylidene)piperidin-1-yl]prop-1-enyl]-4-(trifluoromethylsulfonyl)-3,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶二氮卓类
• 英文名称: 7-[(E)-3-oxo-3-[4-(1,3-thiazol-2-ylmethylidene)piperidin-1-yl]prop-1-enyl]-4-(trifluoromethylsulfonyl)-3,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2-one
• 化学式: C₂₁H₂₀F₃N₅O₄S₂
• 分子量: 527.5
• InChiKey: PPRBUDMUULSYNP-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  149
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• [EN] FUSED PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS PYRIDINE FONDUS, EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014072930A2

  公开（公告）日：2014-05-15

  The present invention relates to fused pyridine derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors, in which P, Q, R1, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.